BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/27/2024 3:11:19 PM | Browse: 160 | Download: 765
 |
Received |
|
2024-04-01 04:47 |
|
Peer-Review Started |
|
2024-04-01 04:47 |
|
First Decision by Editorial Office Director |
|
2024-05-11 08:11 |
|
Return for Revision |
|
2024-05-11 08:11 |
|
Revised |
|
2024-05-13 12:38 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-06-13 02:41 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-06-13 07:04 |
|
Articles in Press |
|
2024-06-13 07:04 |
|
Edit the Manuscript by Language Editor |
|
2024-06-19 09:32 |
|
Typeset the Manuscript |
|
2024-06-28 07:46 |
|
Publish the Manuscript Online |
|
2024-08-27 15:11 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Editorial |
| Article Title |
Macrophage modulation with dipeptidyl peptidase-4 inhibitors: A new frontier for treating diabetic cardiomyopathy?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Saeed Mohammadi and Ahmed Al-Harrasi |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ahmed Al-Harrasi, PhD, Full Professor, Natural and Medical Sciences Research Center, University of Nizwa, Birkat Al Mauz, PO Box 33, Nizwa 616, Oman. aharrasi@unizwa.edu.om |
| Key Words |
Diabetic cardiomyopathy; Macrophage; Dipeptidyl peptidase-4 inhibitor; Teneligliptin; NLRP3 inflammasome; Glucagon-like peptide-1 |
| Core Tip |
Targeting macrophage function could be introduced as a new approach for managing diabetic cardiomyopathy. Chronic hyperglycemia interrupts the balance between pro-inflammatory and anti-inflammatory subtypes of macrophages, promoting inflammation and tissue damage. The dipeptidyl peptidase-4 inhibitors, used for diabetes, might offer cardioprotective benefits by influencing macrophage activity and promoting an anti-inflammatory environment. |
| Publish Date |
2024-08-27 15:11 |
| Citation |
Mohammadi S, Al-Harrasi A. Macrophage modulation with dipeptidyl peptidase-4 inhibitors: A new frontier for treating diabetic cardiomyopathy? World J Diabetes 2024; 15(9): 1847-1852 |
| URL |
https://www.wjgnet.com/1948-9358/full/v15/i9/1847.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v15.i9.1847 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
